A Review of Nanotechnology for Targeted Anti-schistosomal Therapy
暂无分享,去创建一个
[1] Tayo Alex Adekiya,et al. PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs? , 2019, Infectious disorders drug targets.
[2] M. Mohammadi,et al. Nanostructured lipid carriers of ivermectin as a novel drug delivery system in hydatidosis , 2019, Parasites & Vectors.
[3] Zhang Mengying,et al. Alendronate-modified polydopamine-coated paclitaxel nanoparticles for osteosarcoma-targeted therapy , 2019, Journal of Drug Delivery Science and Technology.
[4] D. Carmena,et al. Cryptosporidium infections in terrestrial ungulates with focus on livestock: a systematic review and meta-analysis , 2019, Parasites & Vectors.
[5] Kei Xian Tan,et al. Binding Characterization of Aptamer-Drug Layered Microformulations and In Vitro Release Assessment. , 2019, Journal of pharmaceutical sciences.
[6] J. Javůrek,et al. Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. , 2019, Journal of autoimmunity.
[7] E. Ruoslahti,et al. Peptide-guided nanoparticles for glioblastoma targeting. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[8] S. Payungporn,et al. Phosphoproteomics analysis of male and female Schistosoma mekongi adult worms , 2019, Scientific Reports.
[9] S. Saleh,et al. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection , 2019, Parasites & Vectors.
[10] B. Pradines,et al. Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug , 2019, RSC advances.
[11] T. Shalaby,et al. Effect of nanoparticles on the therapeutic efficacy of praziquantel against Schistosoma mansoni infection in murine models , 2019, Journal of Parasitic Diseases.
[12] J. A. Sarabia-Sainz,et al. Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma , 2019, Molecules.
[13] S. Grant,et al. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. , 2019, Nanomedicine : nanotechnology, biology, and medicine.
[14] O. Feron,et al. Antibody-functionalized gold nanoparticles as tumor-targeting radiosensitizers for proton therapy. , 2019, Nanomedicine.
[15] Juan Carlos del Alamo,et al. Quantifying the mechanics of locomotion of the schistosome pathogen with respect to changes in its physical environment , 2019, bioRxiv.
[16] G. G. Mekonnen,et al. In-depth proteomic characterization of Schistosoma haematobium: Towards the development of new tools for elimination , 2018, bioRxiv.
[17] Richard Barnett,et al. Schistosomiasis , 2018, The Lancet.
[18] A. Khamesipour,et al. Novel Nanosized Chitosan-Betulinic Acid Against Resistant Leishmania Major and First Clinical Observation of such parasite in Kidney , 2018, Scientific Reports.
[19] L. El-Khordagui,et al. Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting , 2018, International journal of nanomedicine.
[20] A. Da'dara,et al. Intravascular Schistosoma mansoni Cleave the Host Immune and Hemostatic Signaling Molecule Sphingosine-1-Phosphate via Tegumental Alkaline Phosphatase , 2018, Front. Immunol..
[21] Wenli Zhang,et al. Particle morphology: an important factor affecting drug delivery by nanocarriers into solid tumors , 2018, Expert opinion on drug delivery.
[22] N. Grishin,et al. Flatworm-specific transcriptional regulators promote the specification of tegumental progenitors in Schistosoma mansoni , 2018, eLife.
[23] Jessica Siltberg-Liberles,et al. Interaction of Peptide Aptamers with Prion Protein Central Domain Promotes α-Cleavage of PrPC , 2018, Molecular Neurobiology.
[24] F. Wang,et al. Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity , 2018, International journal of nanomedicine.
[25] A. J. Walker,et al. Glucose Uptake in the Human Pathogen Schistosoma mansoni Is Regulated Through Akt/Protein Kinase B Signaling , 2017, The Journal of infectious diseases.
[26] L. Rolim,et al. Schistosomiasis: Drugs used and treatment strategies. , 2017, Acta tropica.
[27] Daniel A. Richards,et al. Forming next-generation antibody–nanoparticle conjugates through the oriented installation of non-engineered antibody fragments† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc02747h , 2017, Chemical science.
[28] U. Simon,et al. The effects of gold nanoparticles functionalized with ß-amyloid specific peptides on an in vitro model of blood-brain barrier. , 2017, Nanomedicine : nanotechnology, biology, and medicine.
[29] R. Arya,et al. Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with Mycobacterium tuberculosis following Isoniazid Therapy , 2017, Front. Immunol..
[30] R. Sinden,et al. Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery , 2017, Nanomedicine : nanotechnology, biology, and medicine.
[31] Silvia Catuogno,et al. Aptamer-Mediated Targeted Delivery of Therapeutics: An Update , 2016, Pharmaceuticals.
[32] O. B. Ozdoganlar,et al. Tip-Loaded Dissolvable Microneedle Arrays Effectively Deliver Polymer-Conjugated Antibody Inhibitors of Tumor-Necrosis-Factor-Alpha Into Human Skin. , 2016, Journal of pharmaceutical sciences.
[33] M. Dkhil,et al. Efficacy of Gold Nanoparticles against Nephrotoxicity Induced by Schistosoma mansoni Infection in Mice. , 2016, Biomedical and environmental sciences : BES.
[34] J. A. Garcia-Salcedo,et al. New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites , 2016, Front. Pharmacol..
[35] J. Covès,et al. From Peptide Aptamers to Inhibitors of FUR, Bacterial Transcriptional Regulator of Iron Homeostasis and Virulence. , 2016, ACS chemical biology.
[36] J. Valdés,et al. Fast evolutionary rates associated with functional loss in class I glucose transporters of Schistosoma mansoni , 2015, BMC Genomics.
[37] M. Gremião,et al. Effectiveness of hyperbaric oxygen for experimental treatment of schistosomiasis mansoni using praziquantel-free and encapsulated into liposomes: assay in adult worms and oviposition. , 2015, Acta tropica.
[38] Rieko Furushima-Shimogawara,et al. Immunogenicity and anti-fecundity effect of nanoparticle coated glutathione S-transferase (SjGST) DNA vaccine against murine Schistosoma japonicum infection. , 2015, Parasitology international.
[39] A. Loukas,et al. A quantitative proteomic analysis of the tegumental proteins from Schistosoma mansoni schistosomula reveals novel potential therapeutic targets. , 2015, International journal for parasitology.
[40] D. Burz,et al. Peptide aptamers: development and applications. , 2015, Current topics in medicinal chemistry.
[41] Ching-Seng Ang,et al. Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas. , 2015, ACS nano.
[42] Mafalda Videira,et al. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[43] Zhipeng Xu,et al. An association of Aquaporin-4 with the immunoregulation of liver pathology in mice infected with Schistosoma japonicum , 2015, Parasites & Vectors.
[44] D. Camidge. Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignore. , 2014, Clinical advances in hematology & oncology : H&O.
[45] M. K. Chourasia,et al. Chitosan-Assisted Immunotherapy for Intervention of Experimental Leishmaniasis via Amphotericin B-Loaded Solid Lipid Nanoparticles , 2014, Applied Biochemistry and Biotechnology.
[46] R. Wilson,et al. Schistosome Feeding and Regurgitation , 2014, PLoS pathogens.
[47] T. Day,et al. Functional Characterization of a Novel Family of Acetylcholine-Gated Chloride Channels in Schistosoma mansoni , 2014, PLoS pathogens.
[48] A. Guidi,et al. Schistosomiasis control: praziquantel forever? , 2014, Molecular and biochemical parasitology.
[49] G. Mor,et al. Targeted cancer therapy--are the days of systemic chemotherapy numbered? , 2013, Maturitas.
[50] M. Gremião,et al. Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay. , 2013, Acta tropica.
[51] S. Burgess,et al. Functions and mechanics of dynein motor proteins , 2013, Nature Reviews Molecular Cell Biology.
[52] Bin Liu,et al. Inhibition of Hepatitis C Virus Infection by DNA Aptamer against Envelope Protein , 2013, Antimicrobial Agents and Chemotherapy.
[53] V. Pillay,et al. Ligand-functionalized nanoliposomes for targeted delivery of galantamine. , 2013, International journal of pharmaceutics.
[54] N. Voelcker,et al. Antibody‐Functionalized Porous Silicon Nanoparticles for Vectorization of Hydrophobic Drugs , 2013, Advanced healthcare materials.
[55] A. S. Verkman,et al. Aquaporins , 2013, Current Biology.
[56] H. Tallima,et al. Novel Therapeutic and Prevention Approaches for Schistosomiasis: Review , 2012, Journal of advanced research.
[57] C. M. Rezende,et al. Oral Vaccination Based on DNA-Chitosan Nanoparticles against Schistosoma mansoni Infection , 2012, TheScientificWorldJournal.
[58] J. Moraes. Antischistosomal Natural Compounds: Present Challenges for New Drug Screens , 2012 .
[59] Chen Wang,et al. Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of Anticancer Drug to MUC1-Positive Cancer Cells In Vitro , 2011, PloS one.
[60] M. Eissa,et al. Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy , 2011, Parasites & Vectors.
[61] R. Veerasamy,et al. Biosynthesis of silver nanoparticles using mangosteen leaf extract and evaluation of their antimicrobial activities , 2011 .
[62] J. Thomas-Oates,et al. Enzymatic Shaving of the Tegument Surface of Live Schistosomes for Proteomic Analysis: A Rational Approach to Select Vaccine Candidates , 2011, PLoS neglected tropical diseases.
[63] L. Cerchia,et al. Targeting cancer cells with nucleic acid aptamers. , 2010, Trends in biotechnology.
[64] J. West,et al. Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer , 2010, International journal of nanomedicine.
[65] C. Shoemaker,et al. Suppressing Glucose Transporter Gene Expression in Schistosomes Impairs Parasite Feeding and Decreases Survival in the Mammalian Host , 2010, PLoS pathogens.
[66] F. Verrey,et al. The Tegument of the Human Parasitic Worm Schistosoma mansoni as an Excretory Organ: The Surface Aquaporin SmAQP Is a Lactate Transporter , 2010, PloS one.
[67] M. Gatton,et al. Suppression of mRNAs Encoding Tegument Tetraspanins from Schistosoma mansoni Results in Impaired Tegument Turnover , 2010, PLoS pathogens.
[68] A. Loukas,et al. Exposed proteins of the Schistosoma japonicum tegument. , 2010, International journal for parasitology.
[69] Zhu Chen,et al. Schistosoma genomics: new perspectives on schistosome biology and host-parasite interaction. , 2009, Annual review of genomics and human genetics.
[70] P. Skelly,et al. The role of tegumental aquaporin from the human parasitic worm, Schistosoma monsoni, in osmoregulation and drug uptake , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[71] Y. Zhang,et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008 , 2009, Parasitology.
[72] J. Utzinger,et al. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis , 2008, Current opinion in infectious diseases.
[73] C. Caffrey,et al. Chemotherapy of schistosomiasis: present and future. , 2007, Current opinion in chemical biology.
[74] Tamir Gonen,et al. The structure of aquaporins , 2006, Quarterly Reviews of Biophysics.
[75] R. Wilson,et al. Proteomic analysis of the schistosome tegument and its surface membranes. , 2006, Memorias do Instituto Oswaldo Cruz.
[76] J. Brouwers,et al. Functions of the tegument of schistosomes: clues from the proteome and lipidome. , 2006, International journal for parasitology.
[77] Zhu Chen,et al. New Perspectives on Host-Parasite Interplay by Comparative Transcriptomic and Proteomic Analyses of Schistosoma japonicum , 2006, PLoS pathogens.
[78] R. Pérez-Sánchez,et al. Proteomic analysis of the tegument and excretory‐secretory products of adult Schistosoma bovis worms , 2006, Proteomics.
[79] K. Longmuir,et al. Effective Targeting of Liposomes to Liver and Hepatocytes In Vivo by Incorporation of a Plasmodium Amino Acid Sequence , 2006, Pharmaceutical Research.
[80] S. Verjovski-Almeida,et al. The tegument surface membranes of the human blood parasite Schistosoma mansoni: A proteomic analysis after differential extraction , 2006, Proteomics.
[81] P. I. Costa,et al. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. , 2005, International journal of pharmaceutics.
[82] A. Capron,et al. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. , 2005, Trends in parasitology.
[83] J. Richter,et al. The impact of chemotherapy on morbidity due to schistosomiasis. , 2003, Acta tropica.
[84] E. Loker,et al. Schistosoma mansoni and Biomphalaria: past history and future trends , 2001, Parasitology.
[85] A. Kohn,et al. Schistosome Calcium Channel β Subunits , 2001, The Journal of Biological Chemistry.
[86] C. Shoemaker,et al. The Schistosoma mansoni host-interactive tegument forms from vesicle eruptions of a cyton network , 2001, Parasitology.
[87] Yuesheng Li,et al. Immunogenicity and immunolocalization of the 22.6 kDa antigen of Schistosoma japonicum , 2000, Parasite immunology.
[88] C. Shoemaker,et al. Induction cues for tegument formation during the transformation of Schistosoma mansoni cercariae. , 2000, International journal for parasitology.
[89] H. Saconato,et al. Interventions for treating schistosomiasis mansoni. , 1999, The Cochrane database of systematic reviews.
[90] D. McManus,et al. Characterisation of a family of Schistosoma japonicum proteins related to dynein light chains. , 1999, Biochimica et biophysica acta.
[91] C. Shoemaker,et al. Glucose Transport and Metabolism in Mammalian-stage Schistosomes. , 1998, Parasitology today.
[92] M. Hediger,et al. Molecular Characterization of a Broad Selectivity Neutral Solute Channel* , 1998, The Journal of Biological Chemistry.
[93] H. Kolbe,et al. Characterization of a schistosome T cell-stimulating antigen (Sm10) associated with protective immunity in humans. , 1997, Molecular and biochemical parasitology.
[94] K. Hoffmann,et al. Molecular Identification of a Schistosoma mansoni Tegumental Protein with Similarity to Cytoplasmic Dynein Light Chains* , 1996, The Journal of Biological Chemistry.
[95] C. Shoemaker,et al. Rapid appearance and asymmetric distribution of glucose transporter SGTP4 at the apical surface of intramammalian-stage Schistosoma mansoni. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[96] A. Agnew,et al. Schistosoma: rate of glucose import is altered by acetylcholine interaction with tegumental acetylcholine receptors and acetylcholinesterase. , 1995, Experimental parasitology.
[97] C. Shoemaker,et al. Immunolocalization of a Schistosoma mansoni facilitated diffusion glucose transporter to the basal, but not the apical, membranes of the surface syncytium , 1995, Parasitology.
[98] A. Choudhury,et al. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice , 1995, Antimicrobial agents and chemotherapy.
[99] J. Cunningham,et al. Cloning, characterization, and functional expression of cDNAs encoding glucose transporter proteins from the human parasite Schistosoma mansoni. , 1994, The Journal of biological chemistry.
[100] R. Prichard,et al. Mechanisms of inactivation of Schistosoma mansoni and mammalian glutathione S-transferase activity by the antischistosomal drug oltipraz. , 1992, Biochemical pharmacology.
[101] W. Harnett,et al. Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro , 1986, Parasitology.
[102] P. Basch,et al. Schistosoma mansoni: cholesterol uptake by paired and unpaired worms. , 1986, Experimental parasitology.
[103] G. L. Uglem,et al. Proterometra macrostoma (Trematoda:Azygiidae): functional morphology of the tegument of the redia. , 1985, International journal for parasitology.
[104] P. Basch,et al. Reproductive development of female Schistosoma mansoni (Digenea: Schistosomatidae) following bisexual pairing of worms and worm segments. , 1984, The Journal of experimental zoology.
[105] H. Mehlhorn,et al. Light and electron microscopic studies on the effect of praziquantel onSchistosoma mansoni, Dicrocoelium dendriticum, andFasciola hepatica (trematoda) in vitro , 1980, Zeitschrift für Parasitenkunde.
[106] R. Pax,et al. A benzodiazepine derivative and praziquantel: Effects on musculature of Schistosoma mansoni and Schistosoma japonicum , 1978, Naunyn-Schmiedeberg's Archives of Pharmacology.
[107] R. Wilson,et al. The formation and turnover of the membranocalyx on the tegument of Schistosoma mansoni , 1977, Parasitology.
[108] E. Bueding,et al. Anatomical localization of glucose uptake by Schistosoma mansoni adults. , 1975, International journal for parasitology.
[109] G. L. Uglem,et al. Sugar transport and metabolism in Schistosoma mansoni. , 1975, The Journal of parasitology.
[110] R. Terry,et al. The killing of adult Schistosoma mansoni in vitro in the presence of antisera to host antigenic determinants and peritoneal cells. , 1973, International journal for parasitology.
[111] Tayo Alex Adekiya,et al. Temperature and rainfall impact on schistosomiasis , 2018 .
[112] S. Takeoka,et al. Smart Liposomes for Drug Delivery , 2018 .
[113] Malcolm K. Jones,et al. Tegument and external Features of Schistosoma (with particular reference to ultrastructure) , 2017 .
[114] H. Tallima,et al. Biochemical and biophysical methodologies open the road for effective schistosomiasis therapy and vaccination. , 2017, Biochimica et biophysica acta. General subjects.
[115] Weidong Chen,et al. Preparation and In Vivo-In Vitro Evaluation of Polydatin-PhospholipidComplex with Improved Dissolution and Bioavailability , 2017 .
[116] A. Loukas,et al. Extracellular vesicles secreted by Schistosoma mansoni contain protein vaccine candidates. , 2016, International journal for parasitology.
[117] M. Kašný,et al. Cercaria of schistosoma , 2016 .
[118] J. Boissier,et al. Schistosomiasis chemotherapy. , 2013, Angewandte Chemie.
[119] M. Katz. Anthelmintics , 2012, Drugs.
[120] B. Fried,et al. Coinfection of Schistosoma (Trematoda) with bacteria, protozoa and helminths. , 2011, Advances in parasitology.
[121] E. Albuquerque,et al. Mammalian nicotinic acetylcholine receptors: from structure to function. , 2009, Physiological reviews.
[122] R. Aman,et al. Schistosoma spp.: Isolation of microtubule associated proteins in the tegument and the definition of dynein light chains components. , 2009, Experimental parasitology.
[123] Manuel Arruebo,et al. Antibody-conjugated nanoparticles for biomedical applications , 2009 .
[124] J. M. Mansour,et al. Chemotherapeutic Targets in Parasites: Targets in the Tegument of Flatworms , 2002 .
[125] D. Cioli,et al. Praziquantel , 2002, Parasitology Research.
[126] S. Weremowicz,et al. Functional and molecular characterization of the human neutral solute channel aquaporin-9. , 1999, The American journal of physiology.
[127] B. Fried,et al. The uptake, localization and transfer of [4-14C]cholesterol in Schistosoma mansoni males and females maintained in vitro. , 1985, Comparative biochemistry and physiology. A, Comparative physiology.
[128] J. K. Frenkel,et al. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study. , 1981, Arzneimittel-Forschung.
[129] D. Clayson,et al. Carcinogenic effects of niridazole. , 1975, Cancer letters.
[130] H. Isseroff,et al. Studies on membrane transport—VIII. Absorption of monosaccharides by Fasciola hepatica , 1974 .